Literature DB >> 6497883

Antibodies against a 23Kd heparin binding fragment of thrombospondin inhibit platelet aggregation.

T K Gartner, D A Walz, M Aiken, L Starr-Spires, M L Ogilvie.   

Abstract

Antiserum against a 23Kd heparin binding fragment of thrombospondin inhibits the aggregation of platelets in response to ADP, collagen or thrombin. The antiserum inhibits the secretion-dependent second phase, but not the primary phase of aggregation of platelets responding to ADP. Although immune serum added during the second phase of ADP-induced aggregation causes some inhibition of secretion, it also causes reversal of aggregation to the level produced during primary aggregation. Since thrombospondin is the endogenous lectin of human platelets, these results support the conclusion that the endogenous lectin mediates, at least in part, the secretion-dependent aggregation of platelets. Our data suggest that the region of thrombospondin which contains the heparin binding domain(s) present in the 23Kd fragment play(s) a critical role in secretion-dependent aggregation of platelets.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6497883     DOI: 10.1016/0006-291x(84)90950-1

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Thrombospondin as a mediator of cancer cell adhesion in metastasis.

Authors:  D A Walz
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

2.  Identification of a new class of inducible receptors on platelets. Thrombospondin interacts with platelets via a GPIIb-IIIa-independent mechanism.

Authors:  M L Aiken; M H Ginsberg; E F Plow
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

3.  Glycoprotein IV mediates thrombospondin-dependent platelet-monocyte and platelet-U937 cell adhesion.

Authors:  R L Silverstein; A S Asch; R L Nachman
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

4.  A monoclonal antibody against human thrombospondin inhibits platelet aggregation.

Authors:  V M Dixit; D M Haverstick; K M O'Rourke; S W Hennessy; G A Grant; S A Santoro; W A Frazier
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

5.  Vitronectin binds to activated human platelets and plays a role in platelet aggregation.

Authors:  E Asch; E Podack
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

6.  The evolution of the thrombospondin gene family.

Authors:  J Lawler; M Duquette; L Urry; K McHenry; T F Smith
Journal:  J Mol Evol       Date:  1993-06       Impact factor: 2.395

7.  Human platelet glycoprotein IIIb binds to thrombospondin fragments bearing the C-terminal region, and/or the type I repeats (CSVTCG motif), but not to the N-terminal heparin-binding region.

Authors:  B Catimel; L Leung; H el Ghissasi; N Mercier; J McGregor
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

8.  Characterization of a cDNA encoding the heparin and collagen binding domains of human thrombospondin.

Authors:  V M Dixit; S W Hennessy; G A Grant; P Rotwein; W A Frazier
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

9.  Platelet thrombospondin mediates attachment and spreading of human melanoma cells.

Authors:  D D Roberts; J A Sherwood; V Ginsburg
Journal:  J Cell Biol       Date:  1987-01       Impact factor: 10.539

10.  Mapping of epitopes for monoclonal antibodies against human platelet thrombospondin with electron microscopy and high sensitivity amino acid sequencing.

Authors:  N J Galvin; V M Dixit; K M O'Rourke; S A Santoro; G A Grant; W A Frazier
Journal:  J Cell Biol       Date:  1985-10       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.